Engerix-B Market Report 2026

Engerix-B Market Overview

• The Engerix-B market growth in the historic period has been driven by high global prevalence of hepatitis b infection, early adoption of recombinant vaccines • Market expansion is supported by expansion of adult vaccination programs, rising focus on healthcare worker safety • Growth Driver: Rising Prevalence Of Hepatitis B Virus Infection Driving Growth In The Market • North America was the largest region in 2025.

What Is Covered Under Engerix-B Market?

Engerix-B is a vaccine that protects against hepatitis B, a severe liver infection caused by the hepatitis B virus (HBV). This vaccine contains hepatitis B surface antigen (HBsAg), a protein from the virus that stimulates the body's immune system to produce antibodies without causing the disease itself. The main types of indications for engerix-B are prevention of hepatitis B virus (HBV) infection, chronic hepatitis B prevention, healthcare workers and high-risk populations, and post-exposure prophylaxis. The engerix-B vaccine prevents hepatitis B virus (HBV) infection by stimulating the immune system to produce antibodies, providing long-term immunity for individuals at risk. It is distributed through various distribution channels, such as hospitals, clinics, vaccination centers, and pharmacies, and used by several end users, including private healthcare providers, long-term care facilities, and educational institutions.

What Is The Engerix-B Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of adult vaccination programs, rising focus on healthcare worker safety, growing vaccination coverage in emerging markets, stronger public health funding, increasing emphasis on preventive healthcare. Major trends in the forecast period include expansion of universal hepatitis b vaccination, focus on preventive immunization programs, rising demand for adult and booster vaccines, strengthening of public health vaccination policies, increased coverage in high risk populations.

Global Engerix-B Market Segmentation

1) By Indication: Prevention Of Hepatitis B Virus (HBV) Infection, Chronic Hepatitis B Prevention, Healthcare Workers And High-Risk Populations, Post-Exposure Prophylaxis 2) By Distribution Channel: Hospitals, Clinics, Vaccination Centers, Pharmacies 3) By End-Use: Private Healthcare Providers, Long-Term Care Facilities, Educational Institutions

What Are The Drivers Of The Engerix-B Market?

The rising prevalence of hepatitis B virus (HBV) infection is expected to propel the growth of the engerix-B market going forward. Hepatitis B virus (HBV) infection is a severe liver condition caused by HBV, potentially resulting in chronic disease, liver damage, and a higher risk of liver cancer. Several factors drive the spread of hepatitis B virus (HBV) infection, such as unprotected sexual contact, blood-to-blood contact, lack of vaccination, and immune system compromise. Engerix-B contains a harmless version of the HBV surface antigen, stimulating the immune system to protect against the virus. It offers long-lasting immunity, reducing the risk of HBV infection and its complications. For instance, in April 2024, according to the World Health Organization, a Switzerland-based government department, global health strategies aim to ensure that 80% of individuals living with chronic hepatitis B and C receive treatment by 2030. Therefore, the rising prevalence of hepatitis B virus (HBV) infection is driving the growth of the engerix-B industry. The rising healthcare expenditure is significantly driving the growth of the engerix-B market in the future. Healthcare expenditure is the overall spending on medical services, goods, and treatments, encompassing public and private sector costs. The aging population increases the demand for healthcare services, driving higher costs for healthcare, long-term care, and pharmaceuticals due to chronic and age-related conditions. Increased healthcare expenditure enhances the accessibility and availability of vaccines like Engerix-B by funding vaccination programs, strengthening healthcare infrastructure, and ensuring affordability. This reduces long-term costs related to treating Hepatitis B and its complications. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rising healthcare expenditure is driving the growth of the engerix-B industry. The rising travel and migration are set to propel the growth of the engerix-B market moving forward. Travel and migration involve the movement of people between different locations, typically across regions or nations, for reasons such as leisure, employment, or resettlement. Travel and migration rise due to several factors, including economic opportunities, educational pursuits, family reunification, climate change, and environmental factors. Engerix-B offers essential protection against Hepatitis B for travelers and migrants, particularly in high-risk regions. Vaccination reduces the risk of infection through exposure to contaminated blood, needles, or bodily fluids, ensuring safer travel and migration. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, in 2023, the UK saw 38.0 million visits, marking an increase of 6.7 million compared to 2022. Meanwhile, UK residents' trips abroad rose from 71.0 million in 2022 to 86.2 million in 2023. Therefore, the rising travel and migration are driving the growth of the engerix-B industry.

Key Players In The Global Engerix-B Market

Major companies operating in the engerix-b market are GlaxoSmithKline plc.

Regional Insights

North America was the largest region in the engerix-B market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Engerix-B Market?

The engerix-B market consists of sales of adjuvants, buffering agents, and excipients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Engerix-B Market Report 2026?

The engerix-b market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the engerix-b industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.